title: Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice.
abstract: The effect of a chronic combined treatment with growth hormone (GH) plus melatonin (Mel) on different age-related processes in cytosolic and nuclear fractions of hearts from SAMP8 mice (2 and 10 months) has been investigated. The parameters studied have been messenger RNA expressions of IL-1, IL-10, NFkBp50, NFkBp52, TNFα, eNOS, iNOS, HO-1, HO-2, BAD, BAX, and Bcl2 and protein expressions of iNOS, eNOS, TNFα, IL-1, IL-10, NFkBp50, NFKbp52, and caspase activity (3 and 9). Our results supported the existence of a proapoptotic and oxidative status together with inflammatory processes in the heart of old mice, with increases of inflammatory cytokines, caspase activity, HO-1, BAX, NFkBp50, and NFkBp52 and decreases of eNOS and Bcl2. Also, we were able to observe the translocation of NFkB to nuclei. The combined treatment was able to partially reduce the incidence of these deleterious changes, showing differences with the separated treatments with GH and Mel as were investigated in previous articles from our group.
authors.affiliation: Department of Physiology, Medical School, University Complutense of Madrid, Avda. Complutense s/n, Madrid, Spain.
authors.forename: Katherine
authors.initials: K
authors.lastname: Forman
authors.forename: Elena
authors.initials: E
authors.lastname: Vara
authors.forename: Cruz
authors.initials: C
authors.lastname: García
authors.forename: Roman
authors.initials: R
authors.lastname: Kireev
authors.forename: Sara
authors.initials: S
authors.lastname: Cuesta
authors.forename: Germaine
authors.initials: G
authors.lastname: Escames
authors.forename: J A F
authors.initials: JA
authors.lastname: Tresguerres
mesh_terms: D000284:Administration, Oral; D000375:Aging / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis; D015415:Biomarkers / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006419:Heme Oxygenase (Decyclizing) / Q000235:genetics / Q000378:metabolism; D019382:Human Growth Hormone / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000235:genetics / Q000378:metabolism; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008297:Male; D008550:Melatonin / Q000008:administration & dosage*; D051379:Mice; D009124:Muscle Proteins / Q000378:metabolism; D009205:Myocarditis / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism*; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D018384:Oxidative Stress; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D015415:Biomarkers; D007375:Interleukin-1; D007527:Isoenzymes; D009124:Muscle Proteins; D016328:NF-kappa B; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D019382:Human Growth Hormone; D016753:Interleukin-10; D019001:Nitric Oxide Synthase; D006419:Heme Oxygenase (Decyclizing); D008550:Melatonin